Published March 7, 2014 | Version v1
Journal article

Comparison of 3D anatomical dose verification and 2D phantom dose verification of IMRT/VMAT treatments for nasopharyngeal carcinoma

  • 1. Department of Radiation Oncology, Beijing Hospital of the Ministry of Health, Beijing 100730 (China)
  • 2. Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060 (China)
  • 3. School of Physics and Engineering, Sun Yat-sen University, Guangzhou 510275 (China)

Description

The two-dimensional phantom dose verification (2D-PDV) using hybrid plan and planar dose measurement has been widely used for IMRT treatment QA. Due to the lack of information about the correlations between the verification results and the anatomical structure of patients, it is inadequate in clinical evaluation. A three-dimensional anatomical dose verification (3D-ADV) method was used in this study to evaluate the IMRT/VMAT treatment delivery for nasopharyngeal carcinoma and comparison with 2D-PDV was analyzed. Twenty nasopharyngeal carcinoma (NPC) patients treated with IMRT/VMAT were recruited in the study. A 2D ion-chamber array was used for the 2D-PDV in both single-gantry-angle composite (SGAC) and multi-gantry-angle composite (MGAC) verifications. Differences in the gamma pass rate between the 2 verification methods were assessed. Based on measurement of irradiation dose fluence, the 3D dose distribution was reconstructed for 3D-ADV in the above cases. The reconstructed dose homogeneity index (HI), conformity index (CI) of the planning target volume (PTV) were calculated. Gamma pass rate and deviations in the dose-volume histogram (DVH) of each PTV and organ at risk (OAR) were analyzed. In 2D-PDV, the gamma pass rate (3%, 3 mm) of SGAC (99.55% ± 0.83%) was significantly higher than that of MGAC (92.41% ± 7.19%). In 3D-ADV, the gamma pass rates (3%, 3 mm) were 99.75% ± 0.21% in global, 83.82% ± 16.98% to 93.71% ± 6.22% in the PTVs and 45.12% ± 32.78% to 98.08% ± 2.29% in the OARs. The maximum HI increment in PTVnx was 19.34%, while the maximum CI decrement in PTV1 and PTV2 were -32.45% and -6.93%, respectively. Deviations in dose volume of PTVs were all within ±5%. D2% of the brainstem, spinal cord, left/right optic nerves, and the mean doses to the left/right parotid glands maximally increased by 3.5%, 6.03%, 31.13%/26.90% and 4.78%/4.54%, respectively. The 2D-PDV and global gamma pass rate might be insufficient to provide an accurate assessment for the complex NPC IMRT operation. In contrast, the 3D-ADV is superior in clinic-related quality assurance offering evaluation of organ specific pass rate and dose-volume deviations

Availability note (English)

Available from http://dx.doi.org/10.1186/1748-717X-9-71; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014203

Additional details

Publishing Information

Journal Title
Radiation Oncology (Online)
Journal Volume
9
Journal Page Range
p. 71
ISSN
1748-717X

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
47066039
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CARCINOMAS; IONIZATION CHAMBERS; PHANTOMS; QUALITY ASSURANCE; RADIATION DOSE DISTRIBUTIONS; RADIOTHERAPY; SPINAL CORD; VERIFICATION
Descriptors DEC
CENTRAL NERVOUS SYSTEM; DISEASES; MEASURING INSTRUMENTS; MEDICINE; MOCKUP; NEOPLASMS; NERVOUS SYSTEM; NUCLEAR MEDICINE; RADIATION DETECTORS; RADIOLOGY; STRUCTURAL MODELS; THERAPY

Optional Information

Copyright
Copyright (c) 2014 Lin et al.
Notes
PMCID: PMC4014203; PUBLISHER-ID: 1748-717X-9-71; PMID: 24606879; OAI: oai:pubmedcentral.nih.gov:4014203; licensee BioMed Central Ltd.